WHAT IS CLAIMED IS:

1. A crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6 herein.

2. Halobetasol propionate having crystalline Form I that produces a powder X-ray diffraction pattern as given in Figure 1, with reflections at 9.9, 11.0, 11.6, 13.6, 14.0, 14.5, 15.1, 16.9, 17.9, 18.1, 19.9, 21.1, 21.3, 21.7, 22.3, 22.6, 23.0, 23.4, 23.7, 24.5, 24.7, 25.4, 25.9, 26.0, 26.9, 28.0, 28.6, and 29.4 ±0.2 degrees 2θ.

3. The crystalline halobetasol propionate Form I as described in claim 2 is further characterized by an infra-red spectrum as given in Figure 7, with strong absorption peaks at 1607, 1627, 1666, 1715, 1733 ±4 cm^{-1}.

4. A process for preparing crystalline halobetasol propionate Form I comprising a step of crystallization from methylene chloride: diethylether mixture.

5. Halobetasol propionate having crystalline Form II that produces a powder X-ray diffraction pattern as given in Figure 2, with reflections at 8.0, 10.2,

11.4, 13.0, 14.9, 16.1, 17.1, 18.2, 19.6, 21.0, 22.0, 22.3, 23.1, 24.1, 25.0, 25.9, 27.3, 28.2, 28.5, and 29.0 ±0.2 degrees 2θ.

6. The crystalline halobetasol propionate Form II as described in claim 5 is further characterized by an infra-red spectrum as given in Figure 8 with strong absorption peaks at 1607, 1618, 1662 and 1723 ±4 cm^{-1}.

7. The crystalline halobetasol propionate Form II as described in claims 5 and 5 is further characterized by melting point of 214.5-215.0°C.

8. A process for preparing crystalline halobetasol propionate Form II comprising a step of crystallization from toluene.

9. A process for preparing crystalline halobetasol propionate Form II comprising a step of heating Form V.

10. A process for preparing crystalline halobetasol propionate Form II comprising a step of heating Form VI.

11. Halobetasol propionate having crystalline Form III that produces a powder X-ray diffraction pattern as given in Figure 3 with reflections at 7.0, 10.1, 11.7, 13.0, 13.5, 14.6, 15.1, 15.5, 16.2, 16.5, 17.7, 18.7, 19.0, 20.0, 20.2, 21.6, 22.3, 22.6, 23.6, 24.4, 24.9, 25.3, 26.4, 26.9, 27.5, and 30.3 ±0.2 degrees 2θ.

12. The crystalline halobetasol propionate Form III as described in claim 10 is further characterized by an infra-red spectrum as given in Figure 9, with strong absorption peaks at 1611, 1627, 1665, 1708, 1742 ±4 cm^{-1}.

13. The crystalline halobetasol propionate Form III as described in claims 11 and 12 is further characterized by melting point of 205.8-209°C.

14. A process for preparing crystalline halobetasol propionate Form III comprising a step of crystallization from isopropanol, acetone, or methylene chloride.

15. A process for preparing crystalline halobetasol propionate Form III comprising a step of heating Form I.

16. A process for preparing crystalline halobetasol propionate Form III comprising a step of heating Form IV.

17. Halobetasol propionate having crystalline Form IV that produces a powder X-ray diffraction pattern with reflections at 6.7, 9.4, 11.5, 12.8, 13.1, 13.6, 13.8, 14.5, 14.8, 15.1, 15.4, 17.4, 18.3, 18.6, 19.1, 19.7, 20.7, 20.9, 21.5, 22.8, 23.6, 24.0, 24.4, 24.7, 25.2, 25.6, 26.4, 26.7, 27.2, 28.2, 28.7 and 28.9 ±0.2 degrees 2θ.

18. The crystalline halobetasol propionate Form IV as described in claim 17 is further characterized by an infra-red spectrum as given in Figure 10, with strong absorption peaks at 1606, 1621, 1664, 1711 and 1727 ±4 cm^{-1}, and three broad hydroxyl absorption peaks at 3304, 3425 and 3580 ±4 cm^{-1}.

19. A process for preparing crystalline halobetasol propionate Form IV comprising a step of crystallization from a methanol-water mixture.

20. Halobetasol propionate having crystalline Form V that produces a powder X-ray diffraction pattern with reflections at 7.2, 8.5, 9.0, 9.5, 10.8, 14.0, 14.3, 15.3, 15.6, 16.2, 16.9, 17.7, 19.0, 20.1, 21.5, 22.9, 23.5, 23.6, 24.4, 25.4, 26.0, 26.9, 27.2, and 29.5 ±0.2 degrees 2θ.

21. A process for preparing crystalline halobetasol propionate Form V comprising a step of crystallization from ethyl acetate.

22. Halobetasol propionate having crystalline Form VI that produces a powder X-ray diffraction pattern as given in Figure 6, with reflections at 8.5, 9.2, 9.7, 10.0, 11.3, 11.6, 12.6, 13.0, 13.4, 13.9, 14.8, 15.3, 15.7, 16.0, 16.4, 16.9, 17.2, 17.6, 18.2, 18.5, 19.4, 19.8, 20.0, 20.4, 21.2, 21.4, 22.3, 22.5, 22.9, 23.4, 23.8, 24.3, 24.4, 25.1, 25.3, 25.5, 25.9, 26.2, 26.7, and 27.2 ±0.2 degrees 2θ.

23. The crystalline halobetasol propionate Form VI as described in claim 22 is further characterized by an infra-red spectrum as given in Figure 18, with strong absorption peaks at 1600, 1614, 1623, 1633, 1664, 1725 and 1735 ±4 cm^{-1}, and two hydroxyl absorption peaks at 3659 (narrow) and 3378 (broad) ±4 cm^{-1}.

24. A process for preparing crystalline halobetasol propionate Form VI comprising a step of crystallization from methanol.

25. Stable topical pharmaceutical compositions prepared from or comprising at least one of the crystalline halobetasol propionate of Forms I-VI as defined in claim 1 as active ingredient therein in combination with a pharmaceutically acceptable carrier.

26. Stable topical pharmaceutical compositions prepared from or comprising at least one of the crystalline halobetasol propionate of Forms I-VI as defined in claim 25, having a similar pharmacokinetic profile to an Ultravate commercial preparation.

27. Stable topical pharmaceutical compositions prepared from or comprising crystalline halobetasol propionate of Form III as defined in claim 25, having a similar pharmacokinetic profile to an Ultravate commercial preparation